Announcement
Announcement Under Regulation 30 (LODR) - USFDA Inspection At Goa Formulation Facility 26 Sep - USFDA inspection at Goa formulation facility ended with five procedural observations; response due in 15 days.
Source: Bse
Unichem Laboratories Limited (UNICHEMLAB)
Small CapPharma stocks · Small cap · NSE
Unichem Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:42 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
69BullishSMA20 -1.3% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 49
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
UNICHEMLABD candles · FIT view+33.9%Latest close ₹504.65 on 2026-10-21
Bar
+0.5%
RSI
39
MACD hist
-4.21
52W pos
55%
2026-10-21O ₹502.20H ₹515.00L ₹473.45C ₹504.65Vol 1.1L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
UNICHEMLABNifty PharmaNifty 500
- UNICHEMLAB
- -14.0%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -7.5 pp
Chart stats
21 Oct 2026- From 52W high
- -26.6%
- 52W range position
- 55%
- ATR (14)
- 5.1%
- Volume vs 20D
- 0.38x
- Avg traded value
- ₹16.6 Cr
- 20D price channel
- ₹473.5 - ₹608
₹687.2
₹278.2 - ₹687.2
₹25.6
Latest completed session
20-session average
42.5% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · UNDERVALUED66
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good55
Revenue +20.1% · PAT NDF YoY
Technical
Bullish69
Price trend and sector-relative-strength timing.
Valuation
Legacy model+74.1%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence71
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 55/100Rev +20% YoY · margin expansion · +10% QoQ
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹633 Cr | +20.1% | +10.1% |
| EBITDA | ₹70 Cr | +218.2% | +45.8% |
| Operating margin | 11.0% | +670 bps | +300 bps |
| PAT | ₹41 Cr | NDF | +272.7% |
| PAT margin | 6.5% | +838 bps | +457 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 30.60
- P/B
- 1.38
- EV/EBITDA
- 12.05
- Market Cap
- 3742.00Cr
Profitability
- ROE
- 3.17%
- ROCE
- 4.13%
- ROA
- 8.23%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 12.00%
- EPS 5Y
- 25.00%
- Revenue 3Y
- 18.00%
- EPS 3Y
- 35.00%
Balance Sheet
- Debt/Equity
- 0.18
- Interest Coverage
- 7.16×
- Altman Z
- 4.38
- Book Value
- 386.00
Cash Flow
- FCF Yield
- 5.29%
- FCF Positive Y
- 6/5
- OCF
- 4.00 Cr
- EPS TTM
- 43.29
Shareholding
- Promoter Hold
- 70.22%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 62%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 633+10.1% vs prev
Net Profit
₹ CrLatest: 41.0+272.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 39.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~1.4% over last month) — short-term momentum negative.
- RSI(14) at 39 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 27% off 52W high · 81% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
76
RS percentile
Stage 2 UptrendEstablished S2
1M return
-6.7%
3M return
-14.0%
6M return
+30.9%
1Y return
+6.8%
RS 1D
+1
RS 20D
-7
Sector rank
#1
Industry rank
#14
Stage evidence
- Price is 10.3% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +6.4%.
50-DMA
price below
200-DMA
price above
S2 entered
10 Jul 2026
S2 age
71 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 111.33+0.98%
RS vs Nifty 500111
Valuation & peers
U-Score 66 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 66 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · UNDERVALUEDValuation25/30
Growth18/25
Quality0/20
Balance Sheet11/15
Cash Flow7/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
66
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
66/100 · legacy band UNDERVALUED
Positive drivers
- FCF yield is supportive at 5.3%.
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 74.1%.
Main drags
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Cash flow is weaker at 7/10; verify the latest quarterly trend.
- Growth is weaker at 18/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
30.6
PB
1.4
EV/EBITDA
12.1
ROE
3.2%
ROCE
4.1%
FCF Yield
5.3%
Debt/Equity
0.2
MoS
+74.1%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
66
Previous: 66
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+74.1%
Previous: +74.1%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
66
66
66
66
66
66
66
66
66
66
66
66
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹613.17
+17.7% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹1,948.05
+74.1% MoS
PEG
1.06
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
KPL
Small
Kwality Pharmaceuticals Limited
Healthcare Services
match 167
54
46.3
22.6%
+4%
FAIR VALUE
RPGLIFE
Small
RPG Life Sciences Limited
Healthcare Services
match 164
57
41.0
19.3%
+13%
FAIR VALUE
VENUSREM
Small
Venus Remedies Limited
Healthcare Services
match 164
67
20.5
15.6%
+59%
UNDERVALUED
VIMTALABS
Small
Vimta Labs Limited
Healthcare Services
match 164
58
31.6
18.9%
+37%
FAIR VALUE
SYNCOMF
Small
Syncom Formulations (India) Limited
Healthcare Services
match 164
66
25.4
17.6%
+48%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Unichem Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
71Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 66th percentile of the scored universe and 54th percentile within Pharma. Main check: results consistency is weak at 27/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
17 docs text-extracted · 5 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
66th percentile
overall median 67 · Pharma: 54th pctile, median 70 · Small: 69th pctile, median 66
Evidence depth
Financial-only
17 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
89
strong · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
48
watch · capital discipline
Results
27
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 70.2%.
- ▸Promoter pledge is zero.
- ▸FCF yield is 5.1%.
- ▸6 years of positive FCF.
Trust risks
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 4.1%.
- ▸ROE is low at 3.2%.
- ▸1/4 latest quarters had positive YoY PAT growth.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Unichem Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Jul - Newspaper publication regarding e-voting information for 63rd Annual General Meeting of the Company.
Source: Bse
Announcement
Announcement Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Clarification On Significant Increase In The Volume Of Security. 11 Jun - Unichem clarifies the share volume increase is market-driven, with no undisclosed corporate event.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Jun - Submission of advertisement published in newspapers regarding notice for transfer of equity shares and unclaimed dividends to Investor Education and Protection Fund (IEPF) Account.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.